Study Evaluating the Association of Antibiotic Measures and Control of Bacterial Resistance
Information source: Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Bacterial Infections
Phase: N/A
Status: Completed
Sponsored by: Wyeth is now a wholly owned subsidiary of Pfizer Official(s) and/or principal investigator(s): Medical Monitor, Study Director, Affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
Summary
Assess efficacy of piperacillin/tazobactam in reducing the cases of colonization and
infection of bacteria.
Clinical Details
Official title: Association of Antibiotic Measures and Control of Bacterial Resistance
Study design: Time Perspective: Prospective
Primary outcome: Endpoints will be efficacy of piperacillin/tazobactam in reducing colonization rates and infection of E coli or K pneumoniae, vancomycin resistant enterococcus and methicillin resistant S aureus
Secondary outcome: Endpoints will be acquisition and infection rate of ESBL producing E coli or K pneumoniae, vancomycin resistant enterococcus and methicillin resistant S aureus
Detailed description:
Primarily, this study is designed to assess the efficacy of piperacillin/tazobactam in
reducing the cases of colonization and infection of extended-spectrum betalactamases (ESBLs)
producing E. coli or K pneumoniae, S aureus methicillin resistant (MRSA) and Enterococcus
vancomycin resistant (VRE). Secondly, this study plans to determine the acquisition rate of
ESBL producing E Coli or K pneumoniae, methicillin resistant S Aureus (MRSA) and vancomycin
resistant Enterococcus spp (VRE), both pre- and post-intervention.
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
All patients admitted in ICU will be enrolled (who qualify for treatment).
Locations and Contacts
Additional Information
Starting date: May 2005
Last updated: February 12, 2013
|